Taurine and Nitrate Supplementation on Thermoregulatory in T2DM

The Effect of Taurine and Nitrate Supplementation on Thermoregulatory Responses in People With Type 2 Diabetes Mellitus.

Anthropogenic warming is increasing the frequency and intensity of extreme heat events. Elevated temperatures raise the risk of mortality and hospital admissions, particularly among people with chronic illnesses such as type 2 diabetes mellitus (T2DM). Globally, around 530 million people live with T2DM , and in the United Kingdom nearly six million are affected, creating a substantial population vulnerable to heat related illness.

People with T2DM are at heightened risk of cardiovascular disease, which can impair cardiac output, a key component of thermoregulation, as it supports increased skin blood flow for heat dissipation. T2DM also attenuates eccrine sweat gland function, peripheral vasodilation, reducing evaporative cooling capacity. These physiological constraints highlight the need for effective strategies to improve heat tolerance in this group.

Recent evidence shows that exogenous taurine supplementation can enhance sweating in healthy individuals, potentially improving heat loss. This study will examine whether acute taurine supplementation, alone or combined with beetroot, can limit rises in core temperature in people with T2DM during an acute extreme heat exposure.

Study Overview

• Status: Not yet recruiting
• Conditions: Type 2 Diabetes
• Intervention / Treatment: Dietary supplement: taurine; Dietary supplement: Beetroot and taurine; Dietary supplement: Placebo

Detailed Description

Anthropogenic warming is increasing the likelihood of extreme heat events. These events, defined as periods of abnormally hot weather lasting several consecutive days, are predicted to rise in both temperature and frequency . Extreme heat increases global mortality with people suffering from chronic conditions being especially vulnerable. A growing body of evidence suggests excess mortality may partly result from increased cardiovascular strain. This is particularly relevant for people with Type 2 Diabetes Mellitus (T2DM) who have both an elevated cardiovascular mortality risk independent of heat stress and a compromised ability to regulate their body temperature during heat stress . This likely explains the increase in hospitalisation and mortality in people with T2DM typically observed during heat waves.

People with T2DM are characterised by progressive insulin resistance over a sustained period, reducing the body's ability to effectively metabolise glucose leading to chronic hyperglycaemia. Consequences of chronic hyperglycaemia are micro and macrovascular dysfunction which lead to an increase in cardiovascular disease (CVD) risk and mortality. Heat stress also produces greater heat strain in people with T2DM compared to the rest of the population . This is potentially derived through an attenuated thermoregulatory response to heat stress in people with T2DM, reducing heat dissipation due to impaired sweating, endothelial and cardiac function , skin blood flow and nitric oxide (NO) bioavailability. These factors increase the risk of heat-related illness. Importantly, advanced heat illness is driven in part by systemic inflammation which highlights the need for targeted interventions that can support endogenous anti inflammatory defences in individual with T2DM during exposure to high heat events.

One such intervention may be supplementation with taurine, an amino acid. Taurine shows promise as a thermoregulatory aid during extreme heat, as it promotes faster onset of sweating, greater sweat loss, reduced heat accumulation and enhanced evaporative cooling in healthy populations. As an antioxidant, taurine may also improve inflammation and redox balance by increasing NO bioavailability via increased stability of tetrahydrobiopterin (BH4) in NO synthase and reduced NO scavenging. Beetroot is another antioxidant rich supplement that also increases the bioavailability of NO via the stepwise reduction of nitrate to nitrite and subsequently to NO. Ultimately, this will improve macro and microvascular function in people with chronic disease and may help with thermoregulation during extreme heat. Taurine and nitrate are well tolerated even at high doses in long term clinical trials, whilst taurine's and nitrates capacity to stabilise mitochondrial function provides a biologically plausible means of reducing heat induced oxidative stress.

Taurine and nitrate may therefore offer safe, low-cost interventions to reduce oxidative stress and inflammation, to enhance blood flow and improve evaporative heat loss during heat stress. We hypothesise that taurine and nitrate supplementation will improve the sweating response and reduce the rate of core temperature rise compared to placebo in people with T2DM after exercise in acute heat event. Secondary hypotheses are that the supplements will improve: (1) macro and micro vascular function (2), skin blood flow and (3) redox balance.

• Study Type: Interventional
• Enrollment (Estimated): 18
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Daniel Piccolo, PhD; Phone Number: +44; Email: daniel.piccolo@port.ac.uk
• Study Contact Backup: Name: Ant I Shepherd, PhD; Phone Number: 5289 +44239284; Email: ant.shepherd@port.ac.uk

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Male or female (post-menopausal) aged 35 years or above.
• Diagnosed with T2DM as defined by the WHO (HbA1c ≥48 mmol/mol).
• Willing and able to give informed consent for participation in the study.
• Able to understand and fully cooperate with the study protocol.

Exclusion Criteria:

• Severe peripheral neuropathy (to the point to which they cannot sense temperature)
• Uncontrolled hypertension (≥180 systolic / 100 diastolic)
• Significant renal impairment (eGFR < 30)
• Diagnosed anhidrosis
• Taking any medication which may interfere with data interpretation or safety
• Who have had a myocardial infarction or cerebrovascular event
• Any cardiac abnormalities which restrict hard exercise
• Any allergies to the ingredients used in the supplements
• BMI >40
• Current smokers or who have stopped within 3 months
• Unable to understand and/or fully cooperate with the study protocol
• Any serious medical condition which would interfere with data interpretation or safety will be excluded from participation.
• Open wounds
• Skin ulcerations (that would interfere with data collection and interpretation or safety)
• Eczema (that would interfere with data collection and interpretation or safety)
• Pre-existing postural hypertension
• Existing cardiac diseases (identified during screening)
• Currently heat acclimated (repeated exposure to hot environments ≥3 sessions in the last 14-21 days)
• Prior heat related illness

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Triple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo; Placebo will include the 20g nitrate placebo from above and 5g of maltodextrin (100% Maltodextrin Carbs, myprotein, UK) which will also be added to 305 mL water.	Dietary supplement: taurine; The taurine supplement will be administered as a 5g (100% taurine powder, myprotein, UK) dose. To taste match the beetroot arm we will use a nitrate depleted powder. The placebo contained 1.6% nitrate (180 mg nitrate; Bio-gen Extracts Private Limited, Karnataka, India). The servings contained 13.33g of nitrate depleted beetroot powder. The remaining 6.67g comprised a sweetener (stevia), flavour (watermelon) and flavouring agents (malic & citric acid). The beetroot powders were prepared by manipulating the processing control parameters (extraction time and temperature) during extract preparation to ensure precise nitrate concentration across the different conditions, particularly for the placebo. Specifically, raw beetroot was extracted with water for 1 h at >90°C with the residue obtained from the first extraction processed to obtain the low nitrate grade material. The NO3- content of beetroot powders were determined by treating the samples with a salicylic acid-sulphuric acid mixture,; Dietary supplement: Beetroot and taurine; 20g of formulated beetroot power containing ~6% nitrate (800mg NO3-; TruBeet; Bio-gen Extracts Private Limited). The servings contained 13.33g of the formulated beetroot powder. The remaining 6.67g comprised a sweetener (stevia), flavour (watermelon) and flavouring agents (malic & citric acid) and 5g (100% taurine powder, myprotein, UK) of taurine will also be added to 305mL water prior to ingestion.; Dietary supplement: Placebo; Placebo will include the 20g nitrate placebo from above and 5g of maltodextrin (100% Maltodextrin Carbs, myprotein, UK) which will also be added to 305 mL water.
Active Comparator: Taurine; The taurine supplement will be administered as a 5g (100% taurine powder, myprotein, UK) dose. To taste match the beetroot arm we will use a nitrate depleted powder. The placebo contained 1.6% nitrate (180 mg nitrate; Bio-gen Extracts Private Limited, Karnataka, India). The servings contained 13.33g of nitrate depleted beetroot powder. The remaining 6.67g comprised a sweetener (stevia), flavour (watermelon) and flavouring agents (malic & citric acid). The beetroot powders were prepared by manipulating the processing control parameters (extraction time and temperature) during extract preparation to ensure precise nitrate concentration across the different conditions, particularly for the placebo. Specifically, raw beetroot was extracted with water for 1 h at >90°C with the residue obtained from the first extraction processed to obtain the low nitrate grade material. The NO3- content of beetroot powders were determined by treating the samples with a salicylic acid-sulphuric acid mixture	Dietary supplement: taurine; The taurine supplement will be administered as a 5g (100% taurine powder, myprotein, UK) dose. To taste match the beetroot arm we will use a nitrate depleted powder. The placebo contained 1.6% nitrate (180 mg nitrate; Bio-gen Extracts Private Limited, Karnataka, India). The servings contained 13.33g of nitrate depleted beetroot powder. The remaining 6.67g comprised a sweetener (stevia), flavour (watermelon) and flavouring agents (malic & citric acid). The beetroot powders were prepared by manipulating the processing control parameters (extraction time and temperature) during extract preparation to ensure precise nitrate concentration across the different conditions, particularly for the placebo. Specifically, raw beetroot was extracted with water for 1 h at >90°C with the residue obtained from the first extraction processed to obtain the low nitrate grade material. The NO3- content of beetroot powders were determined by treating the samples with a salicylic acid-sulphuric acid mixture,; Dietary supplement: Placebo; Placebo will include the 20g nitrate placebo from above and 5g of maltodextrin (100% Maltodextrin Carbs, myprotein, UK) which will also be added to 305 mL water.
Active Comparator: Beetroot and Taurine; 20g of formulated beetroot power containing ~6% nitrate (800mg NO3-; TruBeet; Bio-gen Extracts Private Limited). The servings contained 13.33g of the formulated beetroot powder. The remaining 6.67g comprised a sweetener (stevia), flavour (watermelon) and flavouring agents (malic & citric acid) and 5g (100% taurine powder, myprotein, UK) of taurine will also be added to 305mL water prior to ingestion.	Dietary supplement: Beetroot and taurine; 20g of formulated beetroot power containing ~6% nitrate (800mg NO3-; TruBeet; Bio-gen Extracts Private Limited). The servings contained 13.33g of the formulated beetroot powder. The remaining 6.67g comprised a sweetener (stevia), flavour (watermelon) and flavouring agents (malic & citric acid) and 5g (100% taurine powder, myprotein, UK) of taurine will also be added to 305mL water prior to ingestion.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Whole body sweat rate	WBSR will be measured by taking a nude body mass (kg). Participants will be shown to a private changing facility in which the scales (Industrial Electronic Weight Indicator, Model 10, Ohaus Corporation, Parsippany, NJ, US) are located, with the screen for the value reading located outside to ensure privacy of the participant. The pre-mass measure will occur during every experimental visit, before the instrumentation section of the visit. Towel dried nude body mass will then be recorded once de-instrumentation has occurred. The equation below will be used to calculate WBSR. WBSR (L/h) equation: (Pre body mass (kg) - Post body mass (kg)) + Fluid intake (L) - Urine output (L) Duration of test (hrs)	Baseline and immediately post heating (3 hour post-baseline)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Local sweat rate:	The Q-sweat (Qsweat Quantitative Sweat Measurement System, WR Medical Electronics Co., Minnesota, USA) will be used to understand LSR during the heat event. Participants will be instrumented with the ventilated sweat capsule and placed on the upper back (mid scapula) and onto the mid anterior forearm. Additionally, measuring the forearm may provide insight into regional differences and any autonomic dysfunction in sudomotor response. This will be measured continuously throughout the investigation through the software TestWorks (TestWorks software, WR Medical Electronics Co., Maplewood, MN, USA). Live data will be gathered during the trials and subsequent data will be processed into one-minute averages across each trial.	through study completion, average 1 week
Rectal temperature Trec	Trec will be measured continuously (1s intervals) throughout each trial. This will be measured via a rectal thermistor (PROACT Temperature Probes, Northamptonshire, United Kingdom).	through study completion, average 1 week
Skin temperature: Tsk	Tsk will be assessed using four skin thermistors (Grant Instruments, Cambridge, UK), at the sites on the right side of the body at the locations, pectoralis major, biceps brachii, mid-thigh and the gastrocnemius. Thermistors will be placed during the instrumentation part at the start of the protocol and will remain on location until the session has concluded. Data will be recorded throughout the whole duration of the experimental protocol. These will be held in place by a Tegaderm™ dressing (Tegaderm™ Dressings, 3M, St. Paul, Minnesota, USA) with additional tape anchoring them to the skin to avoid movement. Minute averages will be recorded for the duration of the protocol and plotted to understand the change in temperature throughout each trial, to provide information on the specific temperatures that have been identified. Mean skin temperature = (0.3*Tpectorlis) + (0.3*Tbicep) + (0.2*Tthigh) + (0.2*Tcalf) *expressed as an indication of multiplication.	through study completion, average 1 week
Mean Body temperature	Mean body temperature will be measured to provide an overall measure of heat gain for the individual through the combination of Trec and Tsk. The weighting of the different measures of temperature is determined by the ambient temperature of the surrounding, as the protocol will be of a hot environment the below equation was chosen over other weightings, which is as below in Equation two (Burton et al., 2025). This will be measured at all time points that Trec and Tsk are taken in conjunction with each other. This will be measured as absolute values in degrees Celsius, for all time points and also be expressed as a delta change from the baseline temperature or between other specific time points chosen, to provide an understanding of the rate of change. Mean body temperature = Tˉsk=0.3(Tchest+Tarm)+0.2(Tthigh+Tcalf)	through study completion, average 1 week
Cardiac output	Using thoracic bio-reactance technology (Physioflow), which will derive cardiac output at rest. Four electrodes are placed on the participant's chest between which a small, painless current is passed.	through study completion, average 1 week
Macrovascular function	Brachial artery flow mediated dilation (FMD) will be used as a measure of endothelial function. Endothelial-dependent function is assessed by measuring FMD in response to a 5 minute ischaemic stimulus, induced by forearm cuff inflation. Measurements will be performed in the supine position on the right arm with the cuff placed distal to the olecranon process. High-resolution duplex ultrasound (SonoSite Edge II, Bothell, Washington, USA) with a 12-MHz multifrequency linear array probe will be used to image the brachial artery at the distal third of the upper arm and simultaneously record the longitudinal B-mode image and Doppler blood velocity trace. The angle of Doppler insonation will be 60°. Images will be optimised, and settings (depth, focus position, and gain) will be maintained between FMD assessments within each individual visit, and the location of the transducer will be recorded and marked on the skin using an indelible marker.	Baseline and immediately post heating (3 hour post-baseline)
Microvascular function	Briefly, following cleaning of the skin surface with water for injection, two perspex rings will be attached to the skin with one acting as an anode, and the other as the cathode. These electrodes will be connected to the iontophoresis controller (MIC 2, Moor Instruments, UK). Both chambers have an 8 mm inner diameter. The anode chamber will be filled with ~ 0.5 mL of ACh (Braun, Melsungen, Germany), with a 1% concentration dissolved in water for injection. The cathode chamber will be filled with ~ 0.5 mL of SNP (Sigma-aldirch, Missouri, USA) with a 0.01% concentration dissolved in water for injection. The protocol for electrical pulses included: four at 25 μA, followed by a single pulse of 50 μA, 100 μA, 150 µA and 200 µA. These pulses will last for 20 seconds with 120 seconds intervals between each pulse where no current will be applied. An interval of five minutes will be given between testing each site (forearm, finger and foot).	Baseline and immediately post heating (3 hour post-baseline)
Heart rate	During the experimental visits participants will wear a Heart Rate monitor (Polar M430, Kempele, Finland) which will continually record data throughout the session. It will be fitted during the instrumentation section of the protocol. This will provide real time data on participants current HR and allow assessment of the task demands placed on the individual. HR will be averaged to one-minute intervals upon analysis of the data.	through study completion, average 1 week
Biomarkers	blood samples will be collected through venepuncture of a vein in the cubital fossa. The collection of the plasma during the investigation session will be taken pre and post simulated heat events. Sample will be drawn at each specified visit/time point into ethylenediaminetetraacetic acid (EDTA) tube (K2, BD, USA) for analysis of plasma [Taurine] and [cysteine], (inflammation markers) [IL-6], [IL-10], [TNF-α], (intestinal permeability), [LBP] and [iFABP] and into lithium heparin (K2, BD, USA) tubes for [nitrate] and [nitrite].	Baseline and immediately post heating (3 hour post-baseline)
Muscle peripheral oxygenation	Near-infrared spectroscopy (NIRS) will be used to measure oxygenation at the periphery of the medial gastrocnemius. Instrumentation and recording of the measure will be done in accordance with previous published methodology in consuming ketone drink for people with T2DM which is as followed. The NIRS device (NIRS; Portamon Artinis Medical Systems, The Netherlands) will be placed 10 cm inferior to the tibial tubercle and 10 cm lateral to the anterior tibial crest. Upon measurement completion, cleaning and shaving (if required) of the area will be undertaken following marking of the area to ensure correct placement of the device. These measures and markings will take place during trial visits. Participants will be shown the device and where it will be placed during the familiarisation visit. Supporting tape will hold the device in place with a darker colour dressing placed over the device to minimise the light affecting the data.	through study completion, average 1 week
Hydration levels:	Participants will be required to provide a urine sample on entry to the laboratory on experimental visits. This will be measured via an osmolality device [Osmocheck, Vitech Scientific, West Sussex, UK] to ensure hydration levels are below >600 mOsm kg-1, for euhydration (Oppliger et al., 2005). Upon obtaining the sample, a pipette will be used to aliquot the urine onto the prism surface of the sensor well. Should hydration levels be greater than this, participants will be required to consume 500 ml of water and wait 30 minutes (Page et al., 2019) before being able to enter the simulated heat event. Participants will be asked to consume 500 ml of water before entering the laboratory on experimental days (Kirby et al., 2024; Notley et al., 2021). After the experimental sessions, participants will provide a further urine sample (if possible), to assess dehydration pre and post simulated heat event.	Baseline and immediately post heating (3 hour post-baseline)
Thermal sensation	Thermal sensation will be assessed during the investigation to provide a subjective rating of how the participants are feeling within the environment. For thermal comfort participants will be asked to rate their perception of satisfaction of the environment from their state of mind. For thermal sensation, participants will be asked to rate their perception of the sensory feeling of the environment around them. Both questions will be measured on a six-point and six-point scale respectively. This will provide a more in detail understanding of the sensory and state of mind of thermal perception. Participants will be provided with a pen and will be asked to draw a line onto the scale regarding their answer. This will then be measured on a visual analogue scale, and be recorded in cm (Stevens et al., 2025). The marker location will be taken as the uppermost and leftmost extent of the ink marking drawn by participants.	through study completion, average 1 week
Heat illness index:	The heat illness symptom index (HISI) will be a perceptual based measure used during the experimental protocol. This measure will be used to assess the risk from the heat exposure that may be being experienced by the participant. The measure will allow a greater informed decision making in the safety of the participant during the simulated heat event. Participants will be encouraged throughout to express any feelings of discomfort or illness at any moment and not waiting for the index measure to take place. This will be measured at baseline (room temperature) upon entry and exit of the environmental chamber, every ten minutes. Higher HISI = worse (more severe heat illness symptoms) Lower HISI = better (fewer or no symptoms) Each symptom is score on a scale of, 0, 1, 2 and 3.	through study completion, average 1 week
Rate of perceived exertion	The scale that will be used is the Borg (1982) rate of perceived exertion (RPE) scale ranging from 6 (no exertion at all) to 20 (maximal exertion). This measure is widely established scale and will be used to help understand how physically demanding the participants are experiencing the protocol. This will be measured in accordance with the timings of the perceptual measures of heat stress. Participants will be familiarised with this scale during the baseline visit. During the experiment, participants will be asked to verbally tell the research team which number on the scale that is currently being experienced.	through study completion, average 1 week
Stroke volume	Using thoracic bio-reactance technology (Physioflow), which will derive stroke volume at rest. Four electrodes are placed on the participant's chest between which a small, painless current is passed.	through study completion, average 1 week
total peripheral resistance	Using thoracic bio-reactance technology (Physioflow), which will total peripheral resistance, at rest. Four electrodes are placed on the participant's chest between which a small, painless current is passed.	through study completion, average 1 week
heart rate	Using thoracic bio-reactance technology (Physioflow), which will derive heart rate at rest. Four electrodes are placed on the participant's chest between which a small, painless current is passed.	through study completion, average 1 week
Thermal comfort	Thermal comfort will be used during the investigation to provide a subjective rating of how the participants are feeling within the environment. For thermal comfort participants will be asked to rate their perception of satisfaction of the environment from their state of mind. For thermal sensation, participants will be asked to rate their perception of the sensory feeling of the environment around them. Both questions will be measured on a six-point and six-point scale respectively. This will provide a more in detail understanding of the sensory and state of mind of thermal perception. Participants will be provided with a pen and will be asked to draw a line onto the scale regarding their answer. This will then be measured on a visual analogue scale, and be recorded in cm. The marker location will be taken as the uppermost and leftmost extent of the ink marking drawn by participants.	[Time Frame: through study completion, average 1 week]

Collaborators and Investigators

• Sponsor: University of Portsmouth
• Collaborators: University of Southampton; Swansea University; Portsmouth Hospitals NHS Trust

Study record dates

Study Major Dates

• Study Start (Estimated): June 1, 2026
• Primary Completion (Estimated): April 1, 2028
• Study Completion (Estimated): April 1, 2028

Study Registration Dates

• First Submitted: May 8, 2026
• First Submitted That Met QC Criteria: June 12, 2026
• First Posted (Actual): June 18, 2026

Study Record Updates

• Last Update Posted (Actual): June 18, 2026
• Last Update Submitted That Met QC Criteria: June 12, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Keywords: heat; taurine; nitrate; climate
• Additional Relevant MeSH Terms: Endocrine System Diseases; Metabolic Diseases; Glucose Metabolism Disorders; Diabetes Mellitus; Nutritional and Metabolic Diseases; Diabetes Mellitus, Type 2; Sulfur Compounds; Organic Chemicals; Hydrocarbons, Acyclic; Hydrocarbons; Alkanes; Alkanesulfonic Acids; Sulfonic Acids; Sulfur Acids; Taurine
• Other Study ID Numbers: 370139; UP/226698 (Other Grant/Funding Number: Trinsic Collagen Ltd)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Fully anonymised research data (with all personal identifiers removed) may be made openly available in a public data repository after the study is completed. This anonymised dataset may be shared under a Creative Commons Attribution (CC BY) licence, meaning it can be freely used by others provided the original study is credited.

Study Data/Documents

1. Study Protocol
   Information identifier: Protocol v1.2

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No